Simulations Plus (NASDAQ:SLP) Stock Rating Lowered by StockNews.com

Simulations Plus (NASDAQ:SLP - Get Free Report) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Monday.

A number of other research analysts also recently weighed in on SLP. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a report on Thursday, October 24th. JMP Securities started coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They issued a "market perform" rating on the stock. BTIG Research cut their price objective on Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Finally, KeyCorp began coverage on Simulations Plus in a research report on Monday, July 29th. They issued an "overweight" rating and a $47.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $54.50.

Simulations Plus Trading Down 1.0 %

NASDAQ:SLP traded down $0.29 during midday trading on Monday, hitting $27.49. 142,296 shares of the stock were exchanged, compared to its average volume of 132,963. The company has a market capitalization of $551.64 million, a price-to-earnings ratio of 56.10 and a beta of 0.71. Simulations Plus has a one year low of $27.22 and a one year high of $51.22. The business has a 50-day moving average price of $32.09 and a two-hundred day moving average price of $39.78.

Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The company had revenue of $18.70 million for the quarter, compared to analysts' expectations of $19.73 million. During the same quarter in the previous year, the company posted $0.18 EPS. The business's revenue was up 19.9% compared to the same quarter last year. Sell-side analysts forecast that Simulations Plus will post 1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total transaction of $625,200.00. Following the transaction, the director now directly owns 3,481,592 shares in the company, valued at $108,834,565.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 40,750 shares of company stock worth $1,352,455 in the last ninety days. Insiders own 20.90% of the company's stock.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in Simulations Plus in the first quarter valued at about $70,000. BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 9.1% in the 1st quarter. BNP Paribas Financial Markets now owns 14,143 shares of the technology company's stock worth $582,000 after acquiring an additional 1,174 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Simulations Plus during the 1st quarter worth approximately $208,000. Vanguard Group Inc. increased its holdings in Simulations Plus by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company's stock valued at $46,710,000 after purchasing an additional 12,636 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in Simulations Plus during the 1st quarter valued at $57,000. 78.08% of the stock is owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.